Biopharma Company Switches to Lonza’s GS System? for Launched Therapeutic

Lonza’s GS Xceed? Gene Expression System is preferred by many biopharmaceutical companies for its proven track record. An example of a world-class biopharmaceutical company using Lonza’s GS System?, is Innovent Biologics Inc. ("Innovent"). They have successfully finished a host cell line switch for their launched product (IBI305), a biosimilar of Bevacizumab, to increase product titers. The license with Lonza gives Innovent complete access to Lonza’s fully integrated GS? toolbox for therapeutic protein expression, which includes vectors, host cell lines and access to optimized media and feeds.????

Lonza's GS System? is powered by GS Xceed?- an industry-known CHOK1SV GS-KO? cell line that can express a diverse range of biologic drugs. The GS System? has a long-proven track record of product success and is familiar to regulators, minimizing diligence and compliance-related costs and delays. Coupled with Lonza’s expertise and ongoing support, the platform de-risks the partnering process to give confidence and peace of mind.??

We are pleased to support Innovent in their change of expression platform to Lonza’s GS Xceed? Gene Expression System and look forward to their continued development of high-quality medicines to provide a diverse range of treatments.?